The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial
Abstract
Objectives: This randomized, controlled clinical trial aims to compare the efficacy and safety of glucocorticoid combined with MMF and glucocorticoid monotherapy for patients with IgG4-related disease. Methods: Sixty-nine patients newly diagnosed with IgG4-related disease were randomly divided into two groups (35 patients in Group I and 34 patients in Group II). Patients in Group I received glucocorticoid monotherapy (0.6-0.8 mg/(kg·day) and tapered gradually); patients in Group II received glucocorticoid combined with MMF therapy (1-1.5 g/day). All the patients were followed up at 1, 3, 6 and 12 months. The primary endpoint was response rate in 12 months and the secondary endpoints were relapse, remission rate and adverse reactions. Results: Group I and Group II shared almost the same efficacy at the 1 month treatment, but during the follow-up, the complete response rate in Group II was much higher than that in Group I at different time points, and the cumulative relapse rate during 1 year of therapy was much higher in Group I than that in Group II (40.00 vs 20.59%). The remission rate was lower in Group I (51.42 vs 76.47%). Relapses were more likely to happen in lung, lacrimal gland, salivary gland, paranasal sinus and kidney. MMF could reduce relapse, especially organs recurrence. No serious adverse reactions occurred in the two groups. Conclusion: Combination treatment with glucocorticoid and MMF was more effective than the monotherapy, and the relapse of IgG4-related disease might be associated with the elevated levels of serum IgG4 and the low glucocorticoid maintenance dose. Trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT02458196.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy
Ghazale, A., Chari, S. T., Zhang, L., Smyrk, T. C., Takahashi, N., Levy, M. J., Topazian, M. D., Clain, J. E., Pearson, R. K., Petersen, B. T., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.12.009 · Cited by 890
Cited by
IgG4-related disease: an update on pathophysiology and implications for clinical care
Perugino, C. A., & Stone, J. H. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0500-7 · Cited by 421
Advances in the diagnosis and management of IgG4 related disease
Lanzillotta, M., Mancuso, G., & Della-Torre, E. (2020) · BMJ · doi:10.1136/bmj.m1067 · Cited by 360
European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations
Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., et al. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620934911 · Cited by 252
Metadata
- Authors
- Yunyun, F., Yu, P., Panpan, Z., Xia, Z., Linyi, P., Jiaxin, Z., Li, Z., Shangzhu, Z., Jinjing, L., Di, W., Yamin, L., Xiaowei, L., Huadan, X., Xuan, Z., Xiaofeng, Z., Fengchun, Z., Yan, Z., & Wen, Z.
- Venue
- Rheumatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-08-14
- Volume
- 58
- Issue
- 1
- Pages
- 52-60
- ISSN
- 1462-0324 (ISSN-L)
- 1462-0332
- OpenAlex
- W2887266409
- Cited by
- 161
- References
- 2
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. https://app.cochat.ai/papers/10.1093/rheumatology/key227
- The paper
- Yunyun, F., Yu, P., Panpan, Z., Xia, Z., Linyi, P., Jiaxin, Z., Li, Z., Shangzhu, Z., Jinjing, L., Di, W., Yamin, L., Xiaowei, L., Huadan, X., Xuan, Z., Xiaofeng, Z., Fengchun, Z., Yan, Z., & Wen, Z. (2019). Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial. Rheumatology. https://doi.org/10.1093/rheumatology/key227
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.